BD launches prefillable glass vaccine syringe

14-Sep-2022

The glass prefillable syringe was designed in collaboration with leading pharmaceutical companies

BD launches prefillable glass vaccine syringe

Global medical tech company BD (Becton, Dickinson and Company) has launched its glass prefillable syringe.

The new BD Effivax glass prefillable syringe was designed in collaboration with leading pharmaceutical companies to meet the complex and evolving needs of vaccine manufacturing.

The BD Effivax will benefit from the $1.2 billion, four-year investment that BD announced in late 2020 to expand and upgrade manufacturing capacity and technology for PFS. As BD plans for the future of vaccinations, including mRNA and those used for COVID-19, the company remains committed to maintaining robust capacity for PFS to help reduce the time and labour required for vaccine preparation with traditional vial formats.

The launch of BD Effivax strategically supports this growth and will create needed efficiencies in end-to-end production.

“As biopharmaceutical companies continue to rapidly grow their vaccine pipelines, demand for PFS is accelerating across the globe – given their proven ability to facilitate faster administration, support dose sparing and reduce vaccine waste,” said Eric Borin, President of BD Pharmaceutical Systems. “The launch of BD Effivax strategically supports this growth and will create needed efficiencies in end-to-end production.”

Sign up for your free email newsletter

Approximately 70% of the top 100 biopharmaceutical companies rely on BD for supply of PFS. BD Effivax will further help customers meet the stringent demands of today’s vaccine manufacturing through design enhancements focused on fill/finish and container reliability. Through improved quality specifications, BD Effivax is designed to reduce the risk of line stoppage and improve the total cost of ownership, manufacturing capacity and supply availability.

Companies